Group items tagged

Contract manufacturing is a complex process involved in producing vaccine products. This type of production usually involves the manufacturing of vaccines in a single step. Contract manufacturers usually produce vaccines at their facilities; however, some contract manufacturers also service the field through the provision of workspace and by taking care of the closing storage and final disposition of finished products. Some contract manufacturers specialize in the manufacture of one or few vaccines. Others manufacture vaccines for a number of diseases. Technological developments in biomanufacturing and biotechnology are expected to drive growth of the global vaccine contract manufacturing market. Biotechnology has witnessed significant growth in the recent past in both developed and emerging economies. According to the India Brand Equity Foundation (IBEF), the Indian biotechnology industry was valued at US$ 63 billion in 2019 and is expected to reach US$ 102 billion by 2025, registering a CAGR of 10.9%. Besides, key biotechnology and pharmaceutical companies are focused on launching vaccines for protection against infectious diseases. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/vaccine-contract-manufacturing-market.html

Alkaline proteases are a type of enzyme that is active from neutral to pH range. An enzyme is any living thing that can be defined as a chemical reaction that changes something else, usually making a change in its shape or composition at some point during the catalytic reaction. The catalytic reaction may be a kinetic one - that is, it changes something because of the energy produced - or it may be a metabolic one - that is, it changes something because of the energy available for the catalytic reaction. Basically, an enzyme performs a number of functions: breaking down complex molecules into simple substances, assembling amino acids into peptide chains, playing a role in metabolism, and so on. The expanding biotechnology industry due to technological advancement is driving the growth of alkaline proteases market. The rise in the investment in research &development activities is again expected to augment market growth. High demand for proteases from the soaps & detergents industry is also projected to foster the market growth of alkaline proteases. Growing hygiene awareness and increasing demand for the food industry for the preparation of food products is also projected to propel the market growth. Furthermore, the growing demand for environmentally friendly products across emerging economies and increasing use of proteases as therapeutic agents is further projected to augment the growth of alkaline proteases market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/advancement-in-biotechnology-sector-has.html

Rise in research and development regarding the development of biopharmaceuticals have fueled the growth of the global biotechnology media, sera and reagents industry. In addition, the constant expansion of biopharmaceutical research is anticipated to create surge the demand on the production and supply chain for cell culture media and reagents market.

The Department of Industrial Policy and Promotion (DIPP) has released a statistic affirming Foreign Direct Investment in the region of pharmaceuticals and drugs. The value of investments will be around US $ 8.81 billion that comes to about Rs 48,828.3 crore in Indian currency. It is predicted that, the biotechnology industry will surpass 11.6 billion dollars by the year 2017

Course "Supplier Management for Medical Device Manufacturers" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Supplier selection and management is one of the critical issues for medical device manufacturers. Suppliers provide materials and services to the device manufacturer, which means that they can be critical to performance and delivery of your device. Neither the FDA nor your notified body regulates your suppliers (with a few exceptions). They expect you to have an effective process to ensure your suppliers perform in the regulatory environment. How well do you understand the requirements for supplier management? Could you pass a regulatory audit or inspection without any issues? This course delivers the tools, templates, and methods to help participants implement an effective and efficient supplier management program. This two-day hands-on course provides a clear understanding of the underlying principles of supplier management. The course uses exercises to solidify understanding. In addition, the course uses FDA Warning Letters to illustrate the points and help you learn from others. As part of the practical implementation, the course includes receiving acceptance activities, outsourced processes, process validation at the suppliers' location, supplier auditing techniques, and supplier issues in management review. The course uses the Global Harmonization Task Force (GHTF) framework, but expands it to cover other issues and techniques important in effective implementation. Why should you attend: Since FDA regulations do not allow them to audit your suppliers unless they make finished medical devices, they require that you have sufficient control over them. But from time to time the FDA makes a reinterpretation of what this means. This happened within the last f 5 years, so if you supplier management program is older than that, you need to make major changes in you supp

Course "Effective and Efficient Internal and Supplier Quality System Auditing for Medical Devices" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Do you want to understand how to do efficient and effective internal and supplier audits that meet all the requirements of your external auditors, but also add value to your company? Are you confused by all the requirements and guidance documents for medical device quality management systems and are tired of wading through all the regulatory language they contain. This course is for those who will do internal or supplier audits, manage an audit process for these or other company audits. This course will provide you with an easy to understand presentation on the auditing process as well as the requirements you will need to audit under ISO 13485 and the FDA Quality System Regulation (cGMP) Both FDA Quality System Regulation (QSR) and ISO 13485 require that companies do internal audits. However, because the FDA does not look at the content of internal audits, some companies do not get feedback on the true effectiveness of their internal audit system from the FDA during FDA Inspections. ISO 13485 auditors do look at internal audits, but are most concerned that you define a process that meets the requirements of the standard and are following your process. Both require that you define Auditor training is required, but this sometimes just requires reading the company's procedure, although most external auditors will look for more than this. Do you need to train new auditors for yours medical device quality management system or to audit your suppliers? Or do you need to improve the training of your internal and supplier auditors so that they add value to these audits? If you need to do either of these, this seminar will provide this training. In addition to auditing skills and hands-on auditing exercises, this seminar will provide an ove

Course "Key Factors to Write an Effective Standard Operating Procedure (SOP) and Work Instructions (WIs)" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Writing SOPs or procedural documents can be challenging at times. However, writing SOPs is overall a straightforward process. However, enforcing what you already created and implemented in the pipeline is another story. The term SOP is very obvious. We have seen "clearly written description of how specific tasks are to be done." Another satisfactory definition would be "detailed written instructions that achieve the uniformity of the performance of a specific function." Is the firm doing what the regulations specify? Is the firm doing what their procedures specify? If you are medical device or a pharmaceutical manufacturer, these definitions come as no surprise because when it comes to FDA regulations and guidance documents "establish" means to define, to document (in writing or electronically) and to implement. The goal and emphasis with FDA is simple. Proof of "Establish" is the foundation. Is the firm doing what the regulations specify? Is the firm doing what their procedures specify? Are the procedures being followed and enforced by company personnel? SOPs are needed in regulated industries to give step-by-step instructions for performing a particular job or task. This session will provide a step-by-step overview and a snapshot of the procedure description, the process and format. The subject matter of a SOP may range from how to operate a piece of machinery to how to log into a particular software program. SOPs ensure consistency and reliability because they require training of all affected parties. This session will address recent enforcement actions for SOP related violations but no surprise. Most of our enforcement actions are documentation related, i.e., SOP or other procedural documents. We will review examples from

Clinical Research Organization for Healthcare provides clinical-study and clinical-trial support for drugs and medical devices, wherein many pharmaceuticals, biotechnology, and medical device industries having operations in the Europe Union states outsource research services to CRO to increase efficiency and improve productivity.

Cancer is a disease caused when cells divide abnormally and uncontrollably and spread into surrounding tissues, which results in formation of a mass called tumor. Head and neck cancer refers to various malignant tumors that develop in or around the mouth, sinuses, nose, larynx, and throat. Moreover, head and neck cancer begin in squamous cells that line moist surfaces such as those inside the throat, nose, and mouth. Infection with human papillomavirus (HPV), excessive alcohol consumption, and chewing tobacco increases the risk of head and neck cancer. Other factors such as hereditary causes, Epstein barr virus infection, radiation exposure, occupational exposure, oral health, salted or preserved foods, excessive consumption of paan also increases the risk of head and neck cancer. Factors such as rise in government initiatives, surge in research and development activities, rise in health care infrastructure, and increase in the patient population are expected to propel the head and neck cancer market. Worldwide, head and neck cancer is the sixth-most common cancer, with around 630,000 people diagnosed every year, resulting in more than 350,000 deaths, according to the National Center for Biotechnology Information. Moreover, tens of millions of individuals are diagnosed with cancer each year and more than half of the patients eventually die from it. Moreover, cancer ranks the second most common cause of death in many countries, following cardiovascular diseases. Read more @ https://sachinbhombe.blogspot.com/2021/03/insights-on-salicylic-head-and-neck.html

The digital genome consists of a complete digital collection of DNA material that occurs within an organism or a cell. It's a simpler method to collect genetic data concerning hereditary disorders and is used extensively by geneticists for a closer look at potential genetic illnesses. It was first intended to be a tool of diagnosis but has evolved into a powerful research tool. The growing popularity of the human genome projects is a prime factor fueling the growth of the digital genome market. According to Forbes, by 2025, it's projected that 100 million genomes will be sequenced. Increasing funding for genomics is another major factor in augmenting market growth. Moreover, growing development in the field of biotechnology due to rising healthcare needs and increasing investment by the government is again driving the market growth. Additionally, the growing demand for personalized medicines coupled with the penetration of new players and start-ups across developing economies is also projected to foster market growth. Furthermore, the increasing prevalence of chronic disease is further projected to propel the growth of the digital genome market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/digital-genome-powerful-tool-for.html

An antacid is simply a substance that neutralizes stomach acids and is typically used to alleviate heartburn, gastric indigestion, or an upset stomach with food. Some antacids are being used in the treatment of diarrhea and constipation. More recently marketed antacids now contain sodium salts of aluminum, magnesium, calcium, or other substances. Antacids are available both over the counter and by prescription. Antacids neutralize stomach acid as they neutralize the alkaline substance in your stomach - the very substance that causes most of the discomfort! In order to be sure that antacids work, it is important to consult your doctor or pharmacist Growing geriatric population suffering GERD, i.e. gastroesophageal reflux disease is expected to drive growth of the global antacid medications market. According to the National Center for Biotechnology Information (NCBI), around 20% of adults in western culture are affected with GERD. According to the same source, the prevalence of GERD in the U.S. was between 18.1% and 27.8% in 2020. GERD is one of the most common gastrointestinal disorders among the geriatric population. According to the World Health Organization (WHO), by 2050, the global population aged 65 years and above is expected to reach around 2 billion increasing from 900 million in 2015. Read More @ https://coherentmarketinsights-blog.blogspot.com/2021/01/antacid-medications-market-is-expanding.html

A gynecological device is a medical device that is used to promote female health or to protect and preserve reproductive health for females. This is a very broad category and includes products such as watches, calculators, bandages, and hygienic towels. While many of these products have been clinically tested and found to be safe for female health, there are still a few devices in the market that pose threats to female reproductive health. Gynecological devices usually fall into three categories: medical devices, biological safety devices, and mechanical devices. Medical devices are those that prevent the risk of injury or trauma to a woman's reproductive organs from medical interventions. Biologic safety devices are those that protect a female's health by promoting female reproductive health. Finally, mechanical devices are those that help maintain a woman's reproductive health and allow her to achieve or reach their desired fertility or pregnancy. The use of any of these unsupervised or unsafe medical procedures poses a risk to a woman's reproductive health and should be avoided at all costs. The main factors driving the growth of the gynecological devices market are the rapid increase of gynecological diseases such as uterine fibroids, endometriosis, and vaginitis and the introduction of new innovative gynecological devices in the market. For instance, according to the U.S. National Center for Biotechnology Information, approximately 97 per 1000 women suffer from gynecological diseases in the U.S., among which approximately 53 per 1000 women suffer from menstrual disorders. Rising awareness about gynecological health and preventive check-up to avoid sexually transmitted diseases (STD) is expected to boost the market growth. Moreover soaring numbers of surgical procedures such as female sterilization, endoscopy, laparoscopy, and ablation are driving the demand for gynecological devices. However strict regulatory orders by governmental bodies across the globe rel

Biosimilars, also known as biologic products, are currently the fastest growing category of medical products in the United States, with sales estimated at more than $40 billion dollars annually. When prescribed by doctors, these products may provide more effective treatment options for patients suffering from a chronic disease or condition. In late August, the FDA held a forum on biosimilars. The topic was "biosimilar medications - what are they, how do they work, and are they safe and effective." Representatives from the FDA, pharmaceutical companies, and biotechnology organizations attended the forum. The forum included individuals who are leading the charge to register biosimilar products for clinical trials. According to the FDA, the agency will begin accepting applications for biologic drugs in late fall of 2020. In Japan, various manufacturers are focused on developing pipelines that contain biosimilar candidates aimed at treating various therapeutic conditions for patients in Japan. For instance, in December 2020, Alvotech and Japanese pharmaceutical company Fuji Pharma agreed on an extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/biosimilars-and-impact-of-covid-19.html

A biologic drug (biologics) is a product that is produced from living organisms or contains components of living organisms. Biologic drugs are widely used to prevent, diagnose, treat, or cure a variety of diseases, including infectious diseases, autoimmune disorders, chronic kidney disease, and cancer. Biologics drugs are derived from a wide variety of natural sources such as human, animal, or microorganisms by using biotechnology. Moreover, Biologics include a wide variety of products such as blood and blood components, vaccines, tissues, allergenic, gene therapy, somatic cells, and recombinant therapeutic proteins. Novel therapies and new technologies are emerging to create new biologics, which holds a prominent future for the biologics market. The market is majorly driven by the increasing prevalence of chronic diseases across the globe, growing capital investment by key players, and higher acceptability and increasing demand for innovative therapies. For instance, according to the National Health Council, around 157 million Americans are expected to have more than one chronic disorder by 2020. Moreover, according to the World Health Organization, diabetes, cancer, and cardiovascular diseases account for around 1.6 million, 9 million, and 17.9 million deaths each year, respectively. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/11/increasing-prevalence-of-chronic.html

Cancer is a disease caused when cells divide abnormally and uncontrollably and spread into surrounding tissues, which results in formation of a mass called tumor. Head and neck cancer refers to various malignant tumors that develop in or around the mouth, sinuses, nose, larynx, and throat. Moreover, head and neck cancer begin in squamous cells that line moist surfaces such as those inside the throat, nose, and mouth. Infection with human papillomavirus (HPV), excessive alcohol consumption, and chewing tobacco increases the risk of head and neck cancer. Other factors such as hereditary causes, Epstein barr virus infection, radiation exposure, occupational exposure, oral health, salted or preserved foods, excessive consumption of paan also increases the risk of head and neck cancer. Factors such as rise in government initiatives, surge in research and development activities, rise in health care infrastructure, and increase in the patient population are expected to propel the head and neck cancer market. Worldwide, head and neck cancer is the sixth-most common cancer, with around 630,000 people diagnosed every year, resulting in more than 350,000 deaths, according to the National Center for Biotechnology Information. Moreover, tens of millions of individuals are diagnosed with cancer each year and more than half of the patients eventually die from it. Moreover, cancer ranks the second most common cause of death in many countries, following cardiovascular diseases. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/head-and-neck-cancer-is-sixth-most.html

In addressing the sectors of biotechnology, healthcare, medical device and pharmaceuticals, our reports offer inclusive analysis, trends and competitors data. To stay ahead in the competition, we identify key concerns and provide solutions for companies in the healthcare sector to reach new heights.

The growing incidence of viral conjunctivitis cases is driving the growth of the viral conjunctivitis drugs market. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S. Additionally, a rising number of research and development activities for enhancing the effectiveness of viral conjunctivitis drugs is again projected to accelerate the growth of the market. For instance, in 2019, iVIEW Therapeutics Inc., a clinical-stage ophthalmology drug development company, announced the dosing of the first patient in Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis. In 2018, Starpharma Holdings Limited, a company headquartered in Australia, received a patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/08/starpharma-holdings-limited-received.html

Technologies, Markets and Companies" compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid and locked nucleic acid.